NCT07010159View on ClinicalTrials.gov

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
PericarditisPericarditis AcuteRecurrent Pericarditis
Interventions
DRUG

KPL-387

administered by subcutaneous injection

DRUG

Placebo

administered by subcutaneous injection

Trial Locations (4)

31904

RECRUITING

Investigational Site 001, Columbus

44195

RECRUITING

Investigational Site 003, Cleveland

60611

RECRUITING

Investigational Site 004, Chicago

66221

RECRUITING

Investigational Site 002, Overland Park

Sponsors
All Listed Sponsors
collaborator

Kiniksa Pharmaceuticals, GmbH

INDUSTRY

lead

Kiniksa Pharmaceuticals International, plc

INDUSTRY